title: The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy.
abstract: Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur upon irradiation. We propose that the targeted inhibition of the TLR9/STAT3 signaling axis in myeloid cells can support the efficacy of local radiotherapy and prevent cancer recurrence.
authors.affiliation: Department of Cancer Immunotherapeutics & Tumor Immunology; City of Hope National Medical Center; Duarte, CA USA.
authors.forename: Marcin
authors.initials: M
authors.lastname: Kortylewski
authors.affiliation: Department of Medical Oncology & Experimental Therapeutics at Beckman Research Institute; City of Hope National Medical Center; Duarte, CA USA.
authors.forename: Sumanta K
authors.initials: SK
authors.lastname: Pal
keywords: IL-6; NF-κB; STAT3; TLR9; angiogenesis; cancer recurrence; myeloid cells; radiotherapy